Australia - inglés - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - ertapenem -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - eprosartan; eprosartan mesylate -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - eprosartan; hydrochlorothiazide -

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

diversey australia pty. limited - chlorhexidine gluconate; glycerine - liquid concentrate - chlorhexidine gluconate guanidine active 60.0 g/l; glycerine solvent other 150.0 g/l - dermatological preps. - dairy cattle | bovine | breeders | calves | dairy cow | growers | lactating cow | milking cow - cracking & chapping of teat | mastitis | subclinical mastitis | udder teat cracking/chapping

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eprosartan mesilate 200mg - film coated tablet - 200 mg - active: eprosartan mesilate 200mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry pregelatinised maize starch purified water

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eprosartan mesilate 300mg - film coated tablet - 300 mg - active: eprosartan mesilate 300mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-s-9603 pregelatinised maize starch purified water

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

viatris limited - eprosartan mesilate 400mg - film coated tablet - 400 mg - active: eprosartan mesilate 400mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink ys-1-14643-a pregelatinised maize starch purified water

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

viatris limited - eprosartan mesilate 735.8mg equivalent to 600 mg eprosartan;   - film coated tablet - 600 mg - active: eprosartan mesilate 735.8mg equivalent to 600 mg eprosartan   excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-s-9603 purified water starch

Estados Unidos - inglés - NLM (National Library of Medicine)

method pharmaceuticals, llc - salsalate (unii: v9mo595c9i) (salsalate - unii:v9mo595c9i) - salsalate 500 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

acella pharmaceuticals, llc - salsalate (unii: v9mo595c9i) (salsalate - unii:v9mo595c9i) - salsalate 500 mg - indications and usage carefully consider the potential benefits and risks of salsalate tablets and other treatment options before deciding to use salsalate tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. contraindications salsalate tablets is contraindicated in patients with known hypersensitivity to salsalate. salsalate tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings – anaphylactoid reactions , and precautions - preexisting asthma ). salsalate tablets is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warn